GW Pharmaceuticals plc is slated to release fourth-quarter and full-year 2019 results on Feb 25.
In the last reported quarter, it posted a positive earnings surprise of 44.8%. The company reported better-than-expected earnings in all of the trailing four quarters, the average positive beat being 40.7%.
Let's discuss the factors that are likely to have influenced the company's performance in the fourth quarter.
For the past few months, the company has been witnessing continued rise in demand and market acceptance for Epidiolex in the United States, as a growing number of physicians are recommending this drug in their prescriptions. This high level of market penetration is likely to have continued in the fourth quarter as well.
Notably, Epidiolex, as the first cannabis-derived drug for patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, is fast capturing the market since its November 2018 launch in the United States.
Through the second half of 2019, the company commercialized Epidiolex, beyond the United States, in select European countries. Markedly, the European Commission’s approval for Epidiolex’s marketing authorization for patients aging more than two years is anticipated to have aided the company’s quarterly revenues.
In terms of coverage determination, the company continues to increase payor access. It earlier expected this to have continued in the fourth quarter as well.
Sativex, which is used to treat muscle spasms, has been gaining popularity. The company believes this will get reflected in its quarterly performance. The CBDV program, which has been performing well, is expected to have continued its stellar performance in the December-end quarter as well.
Preliminary Sales Results
Going by the company’s preliminary announcement for the fourth-quarter and full-year 2019 net product sales, GW Pharmaceuticals expects to report total net product sales of around $108 million in the quarter and approximately $309 million for the year.
Epidiolex’s net product sales are projected at $104 million for the October-December period and $296 million for the full year.
The Zacks Consensus Estimate for total revenues of $104.9 million suggests significant growth from the prior quarter’s $6.7 million. The consensus mark for loss per share is pegged at 52 cents, 77.9% narrower than the loss of $2.35 reported in the year-earlier period.
What Our Quantitative Model Predicts
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. But this is not the case here as you will see below.
Earnings ESP: GW Pharmaceuticals has an Earnings ESP of -1.94%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:GW Pharmaceuticals currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to post an earnings beat this quarter.
Tandem Diabetes Care, Inc. TNDM currently sports a Zacks Rank of 1 and has an Earnings ESP of +86.44%.
Nevro Corp. NVRO carries a Zacks Rank of 2 and has an Earnings ESP of +3.45%, at present.
HealthEquity, Inc. HQY holds a Zacks Rank #3 and has an Earnings ESP of +18.56%, currently.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>